The FDA takes a broader approach to approving drug therapy.
Historically, the FDA has approved cancer drugs based on a particular cancer’s location in the body, but that may be changing.
Last year, the FDA said Keytruda, a new immunotherapy drug by Merck, could be used to treat all cancers that share a genetic abnormality called mismatch repair (MMR) deficiency. It was the first time the FDA approved a cancer drug based on a common biomarker rather than the cancer type — lung vs. breast, for example...
Want to read the whole article?
Select from the following options:
* offer valid for new subscribers only